Directors Share Purchase

Advanced Medical Solutions Grp PLC
03 July 2007


For immediate release                                                3 July 2007

                      Advanced Medical Solutions Group plc
                             ('AMS' or 'the Group')

                          Directors purchase of shares

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, announces today that Geoffrey Vernon, Chairman, has
purchased 100,000 Ordinary Shares at 20.5p; Don Evans, Chief Executive Officer,
has purchased 20,000 shares at 20.25p; Chris Meredith, Commercial Director, has
purchased 10,000 shares at 20.25p and Steve Bellamy, non-Executive Director, has
purchased 100,000 shares at 20.25p .

As a result, Geoffrey Vernon has a beneficial and non beneficial interest in
960,000 ordinary shares, representing 0.67% of the issued share capital of the
Company; Don Evans has a beneficial and non beneficial interest in 763,859
ordinary shares, representing 0.53% of the issued share capital of the Company;
Chris Meredith has a beneficial and non beneficial interest in 55,136 ordinary
shares, representing 0.04% of the issued share capital of the Company and Steve
Bellamy has a beneficial and non beneficial interest in 100,000 ordinary shares,
representing 0.07% of the issued share capital of the Company.

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer                      Tel: [phone]
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications
Mark Court, Mary-Jane Johnson                          Tel: [phone]


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing topical wounds sold direct to hospitals or through
distributors.

AMS's technology and products currently serve the majority of the key global
markets and strategic partners.


                      This information is provided by RNS
            The company news service from the London Stock Exchange